Comprehensive Clinical and Molecular Characterization of KRASG12C-Mutant Colorectal Cancer.

ABSTRACT: KRAS p.G12C mutations occur in approximately 3% of metastatic colorectal cancers (mCRC). Recently, two allosteric inhibitors of KRAS p.G12C have demonstrated activity in early phase clinical trials. There are no robust studies examining the behavior of this newly targetable population. We queried the MD Anderson Cancer Center data set for patients with colorectal cancer who harbored KRAS p.G12C mutations between January 2003 and September 2019. Patients were analyzed for clinical characteristics, overall survival (OS), and progression-free survival (PFS) and compared against KRAS nonG12C. Next, we analyzed several internal and external data sets to assess immune signatures, gene expression profiles, hypermethylation, co-occurring mutations, and proteomics. Among the 4,632 patients with com

SUBMITTER: Henry JT 

PROVIDER: S-EPMC8232253 | biostudies-literature | 2021

REPOSITORIES: biostudies-literature